Orgenesis, Biosequel partner to conduct clinical trials for Type 1 diabetes in Russia

The two companies will collaborate on conducting clinical trials in Russia.

Biosequel founder and practicing Israeli physician Vitaly Shabadash said: "We have searched the world over for a company as progressive and innovative as Orgenesis.

"Orgenesis is on the cutting edge of medical development in driving the industry towards a practical cure for Type 1 Diabetes and we are honored to work with them in Russia to facilitate the human clinical trials in this country."

Orgenesis is an innovator in the technology of "cellular trans-differentiation." This process involves re-programming one adult cell type to function like an adult cell of a different type.

Orgenesis is developing Autologous Insulin Producing Cells, which means a type 1 diabetic patient’s own liver cells would be transformed into glucose-responsive insulin-producing liver cells in the hope of freeing the patient from insulin dependence.

Orgenesis CEO Vered Caplan said: "We are pleased that Biosequel has chosen to collaborate with us and make use of the unique research facilities at the new state-of-the-art Yauza Medical Center.

"Biosequel has the right people and the resources to take our research to the next stage of clinical development and regulatory approvals."